BRAF Inhibition in <i>BRAF</i>^V600-Mutant Gliomas: Results From the VE-BASKET Study

Abstract

Vemurafenib demonstrated evidence of durable antitumor activity in some patients with <i>BRAF</i>^V600-mutant gliomas, although efficacy seemed to vary qualitatively by histologic subtype. Additional study is needed to determine the optimal use of vemurafenib in patients with primary brain tumors and to identify the mechanisms driving differential responses across histologic subsets.